All In Biotech

NDA 019661 · Cheplapharm

Cytovene

Ganciclovir Sodium · Injection

NovelPriority reviewOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: May 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Jun 23, 1989

Approved uses

3

Original approval plus efficacy supplements

Registered trials

196

46 Phase 3, 21 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 6, 2018 Supplement 37 · Efficacy Label
  • May 15, 1992 Supplement 8 · Efficacy
  • Jun 23, 1989 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • CYTOVENE · GANCICLOVIR SODIUM EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ganciclovir" as an intervention, any sponsor and status, largest first.

All 196 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Cytovene* (Ganciclovir Sodium*) · HCPCS J1570

2024 spending

$211K

Beneficiaries

186

917 claims

Per beneficiary

$1,135

2024 ASP limit $39.36 per unit

View as table
YearSpending
2020$199,278
2021$571,774
2022$388,116
2023$282,951
2024$211,121

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 597 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.